METAP2 and type 2 diabetes mellitus: MetAP2 inhibitors have emerged as a significant class of compounds targeting a variety of diseases, including cancer, angiogenesis-related conditions, immune modulation, inflammation, and metabolic disorders such as obesity and T2DM.